Paul Fernyhough, BSc, PhD

Dr. Paul Fernyhough is a renowned researcher in the field of neurodegeneration and neuronal regeneration. Born and educated in East London, UK, he received his Bachelor of Science degree in biological sciences at the University of Essex and went on to perform his PhD in biochemistry at the University of Sheffield.

After completing his PhD, Dr. Fernyhough embarked on a journey of postdoctoral research, honing his skills and expanding his knowledge at esteemed institutions such as Colorado State University, Kings College London, and as a Wellcome Trust Postdoctoral Fellow at St. Bartholomew’s Medical College.

In 1998, Dr. Fernyhough joined the School of Biological Sciences (now the Faculty of Life Sciences) at the University of Manchester as a fully tenured lecturer. He spent over five years at the University of Manchester before moving to Canada to join the Max Rady College of Medicine as a professor of pharmacology and therapeutics.

Throughout his career, Dr. Fernyhough has been dedicated to understanding the mechanisms of nerve damage and identifying key signaling pathways that are impaired in animal models of neuropathy and Alzheimer’s disease. His research interests include cholinergic signaling, GPCR signaling, bioenergetics, drug design, and muscarinic receptors.

In addition to his academic pursuits, Dr. Fernyhough is also the director of the division of neurodegenerative disorders at the St. Boniface Hospital Albrechtsen Research Centre, and is a co-founder of WinSanTor Inc., a small start-up biotech company that supports clinical trials in the area of peripheral neuropathy. He is also affiliated with the Manitoba Neuroscience Network.

Dr. Fernyhough's research is making significant contributions towards improving the lives of millions of people suffering from diabetes and other neurodegenerative disorders.

Education

Doctor of Philosophy in Biochemistry, University of Sheffield (1984)

Bachelor of Science in Biology, University of Essex (1981) with 2.1 Honours